STAT+: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy

The FDA’s Peter Marks joined STAT for an interview about accelerated approval and other issues — and seemed inclined to grant full approval to Sarepta’s Duchenne gene therapy.
Click here to view original post